ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study

Paolo Strati, Michelle A. Fanale, Yasuhiro Oki, Francesco Turturro, Luis E. Fayad, Nancy L. Bartlett, Douglas Gladstone, Yvette L. Kasamon, Carol S. Portlock, Wyndham H. Wilson, Andre Goy, Anas Younes, Hun Ju Lee

Research output: Contribution to journalLetter

Original languageEnglish (US)
Pages (from-to)e65-e67
JournalHaematologica
Volume104
Issue number2
DOIs
StatePublished - Feb 1 2019

ASJC Scopus subject areas

  • Hematology

Cite this

Strati, P., Fanale, M. A., Oki, Y., Turturro, F., Fayad, L. E., Bartlett, N. L., Gladstone, D., Kasamon, Y. L., Portlock, C. S., Wilson, W. H., Goy, A., Younes, A., & Lee, H. J. (2019). ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study. Haematologica, 104(2), e65-e67. https://doi.org/10.3324/haematol.2018.199844